Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with Next-Generation Targeted Strategies | DelveInsight
The platinum-resistant ovarian cancer market is expanding due to a growing unmet need, as many patients relapse after first-line platinum therapies, driving demand for novel second- and later-line treatments. Advances in targeted therapies and immunotherapies are broadening treatment options and attracting investment. The launch of emerging therapies such as Corcept Therapeutics (relacorilant), Advenchen Laboratories (catequentinib), Regeneron Pharmaceuticals (ubamatamab), and others will further fuel the market.
LAS VEGAS, Oct. 9, 2025 /PRNewswire/ -- DelveInsight's Platinum-Resistant Ovarian Cancer Market Insights report includes a comprehensive understanding of current treatment practices, platinum-resistant ovarian cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
Nenhum comentário